Our T-cell therapy targeting the NY-ESO peptide, which is present across multiple cancer types, is partnered with GSK. Following option exercise, the NY-ESO program is being transferred to GSK during a transition period.
Our NY-ESO SPEAR T-cell has been used in multiple Phase 1/2 clinical trials in patients with solid tumors and haematological malignancies, including synovial sarcoma, myxoid round cell liposarcoma, multiple myeloma, melanoma, NSCLC and ovarian cancer. We have seen responses and evidence of tumor reduction in patients with both synovial sarcoma and multiple myeloma.The initial data suggest a promising risk/benefit profile. Breakthrough therapy designation in the United States and PRIME regulatory access in Europe have been granted to the NY-ESO SPEART T-cell.